Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
DE000A289VV1
Fri, 15.12.2023       HAEMATO AG
GBC AG DE000A289VV1

Delisting of the HAEMATO share to take place from February 2023; price potential not yet exhausted; GBC-rating and GBC-price target suspended   HAEMATO has announced the termination of the inclusion of the shares in the open market of 30 November 2023. The shares are to be delisted after expiry of the notice period, at the latest by the end  [ … ]
Technical analysis
To the publication
Wed, 13.12.2023       Haemato AG
First Berlin Equity Research GmbH DE000A289VV1

First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN: DE000A289VV1) veröffentlicht. Analyst Ellis Acklin hat seine bisherige Buy-Empfehlung und sein bisheriges Kursziel von EUR 34,00 wegen des bevorstehenden Delistings zurückgenommen. Zusammenfassung: Haemato wird die Notierung ihrer Aktien im Open Market der Frank [ … ]
Technical analysis
To the publication
Mon, 18.09.2023       Haemato AG
First Berlin Equity Research GmbH DE000A289VV1

First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN: DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und erhöht das Kursziel von EUR 33,00 auf EUR 34,00. Zusammenfassung: Das Sechsmonatsbericht lag nahe an unseren Prognosen und verdeutlichte die schlankere operative Kostenstr [ … ]
Technical analysis
To the publication
Thu, 14.09.2023       HAEMATO AG
GBC AG DE000A289VV1

H1 2023: Turnover and EBIT above our expectations; forecasts and target price slightly raised; BUY rating confirmed   In the first half of 2023, HAEMATO AG achieved a revenue increase of 10.5 % to € 133.64 million (previous year: € 120.97 million) and thus exceeded our expectations. This sales development, which is separated accord [ … ]
Technical analysis
To the publication
Fri, 14.07.2023       HAEMATO AG
GBC AG DE000A289VV1

- Compulsory manufacturer discounts burden 'Specialty Pharma' segment - Lifestyle & Aesthetics' segment should grow in 2023; high potentials available with Botox launch - Increase in profitability expected   As expected, HAEMATO AG reports a decline in revenue to € 248.14 million (previous year: € 285.04 million) for the past f [ … ]
Technical analysis
To the publication
Fri, 14.07.2023       HAEMATO AG
GBC AG DE000A289VV1

- Compulsory manufacturer discounts burden 'Specialty Pharma' segment - Lifestyle & Aesthetics' segment should grow in 2023; high potentials available with Botox launch - Increase in profitability expected   As expected, HAEMATO AG reports a decline in revenue to € 248.14 million (previous year: € 285.04 million) for the past f [ … ]
Technical analysis
To the publication
Wed, 21.06.2023       Haemato AG
First Berlin Equity Research GmbH DE000A289VV1

First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN: DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und erhöht das Kursziel von EUR 33,00 auf EUR 34,00. Zusammenfassung: Haemato hat das Jahr mit einem starken ersten Quartal begonnen und ist auf gutem Weg, unsere Ziele fü [ … ]
Technical analysis
To the publication
Wed, 21.06.2023       Haemato AG
First Berlin Equity Research GmbH DE000A289VV1

First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN: DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und erhöht das Kursziel von EUR 33,00 auf EUR 34,00. Zusammenfassung: Haemato hat das Jahr mit einem starken ersten Quartal begonnen und ist auf gutem Weg, unsere Ziele fü [ … ]
Technical analysis
To the publication
Mon, 17.04.2023       HAEMATO AG
GBC AG DE000A289VV1

Preliminary 2023 figures: Revenue and earnings development in line with expectations; Guidance issued against the backdrop of increased mandatory discounts; Target price: € 31.70; Rating: BUY   According to preliminary figures, HAEMATO AG had to accept a decline in turnover of 12.9% to € 248.2 million (previous year: € 285.0 mi [ … ]
Technical analysis
To the publication
Mon, 17.04.2023       HAEMATO AG
GBC AG DE000A289VV1

Preliminary 2023 figures: Revenue and earnings development in line with expectations; Guidance issued against the backdrop of increased mandatory discounts; Target price: € 31.70; Rating: BUY   According to preliminary figures, HAEMATO AG had to accept a decline in turnover of 12.9% to € 248.2 million (previous year: € 285.0 mi [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 07.07.2024, Calendar Week 27, 189th day of the year, 177 days remaining until EoY.